Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)

Trial Profile

Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary) ; Baricitinib (Primary) ; Canakinumab (Primary) ; Hydroxychloroquine (Primary) ; Lopinavir/ritonavir (Primary) ; Sarilumab (Primary) ; Tocilizumab (Primary) ; Umifenovir (Primary)
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Agranulocytosis; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; COVID-19 pneumonia; Haematological disorders; Lymphoma; Multiple myeloma; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms CHRONOS19
  • Most Recent Events

    • 17 Jun 2021 Results (n=106) of subgroup analysis assessing disease course of COVID-19, treatment and first vaccination data in patients with CML in Russian Federation presented at the 26th Congress of the European Haematology Association
    • 17 Jun 2021 Results (n=575; data cut off date: January 27, 2021) of subgroup analysis assessing the treatment outcomes and identify risk factors associated with higher mortality in this group of patients with acute leukemia and COVID-19, presented at the 26th Congress of the European Haematology Association.
    • 04 Jan 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top